Tau and Type IV Collagen Fragments as Serum Biomarkers in Recurrent Glioblastoma

Glioblastoma (GBM) remains a devastating disease with limited treatment options and a lack of reliable, non-invasive biomarkers to guide therapy and predict outcomes.

In this study, we identify serum biomarkers (Tau-A and C4G) that are significantly elevated in patients with recurrent GBM and that show a strong association with improved overall survival (OS) when treated with nivolumab and bevacizumab. Unlike conventional imaging or invasive methods, these serum biomarkers provide a non-invasive, dynamic, and easily accessible approach to track disease progression and response to treatment.

Tau-A and C4G offer a potential tool to stratify patients, monitor treatment efficacy, and predict survival outcomes in GBM, addressing a critical gap in current clinical practice.

We therefore encourage clinicians and researchers to explore the validation and integration of Tau-A and C4G into clinical trials and routine practice to unlock new possibilities in personalized GBM management.

Article: Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab